SRR1316624
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.513
- PANCREAS_BETA_CELLS+0.408
- APICAL_SURFACE+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.258
- COAGULATION+0.254
- ANGIOGENESIS+0.252
- INFLAMMATORY_RESPONSE+0.227
- MYOGENESIS+0.221
- SPERMATOGENESIS+0.172
- KRAS_SIGNALING_UP+0.117
Top 10 suppressed
- MYC_TARGETS_V1-0.687
- UNFOLDED_PROTEIN_RESPONSE-0.587
- OXIDATIVE_PHOSPHORYLATION-0.553
- PROTEIN_SECRETION-0.548
- MYC_TARGETS_V2-0.546
- DNA_REPAIR-0.530
- MTORC1_SIGNALING-0.528
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.444
- PI3K_AKT_MTOR_SIGNALING-0.441
- TGF_BETA_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1394713 | GTEX | — | 0.973 |
| 2 | SRR1474886 | GTEX | — | 0.971 |
| 3 | SRR1448226 | GTEX | — | 0.971 |
| 4 | SRR1451964 | GTEX | — | 0.968 |
| 5 | BS_MQCKXD60 | Glial-neuronal tumor NOS | — | 0.967 |
| 6 | SRR1337431 | GTEX | — | 0.967 |
| 7 | SRR1382956 | GTEX | — | 0.966 |
| 8 | SRR1416754 | GTEX | — | 0.965 |
| 9 | SRR1339549 | GTEX | — | 0.965 |
| 10 | BS_0X9EGHY2 | low-grade glioma | — | 0.963 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.513 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.408 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.258 | Inavolisib | — uncovered |
| COAGULATION | 0.254 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.252 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.227 | Idelalisib | — uncovered |
| MYOGENESIS | 0.221 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.172 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.117 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.113 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.097 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.066 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.058 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.053 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.035 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.029 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.022 | Inavolisib | — uncovered |